Login Register Cart 0
Generic placeholder image

Current Drug Therapy

Editor-in-Chief

ISSN (Print): 1574-8855
ISSN (Online): 2212-3903

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Mini-Review Article

Protective Effect of Statin Therapy in Ankylosing Spondylitis

Author(s): Fataneh Tavasolian, Elham Abdollahi, Robert D. Inman* and Amirhossein Sahebkar*

Volume 20, Issue 1, 2025

Published on: 23 January, 2024

Page: [1 - 7] Pages: 7

DOI: 10.2174/0115748855272102231205111945

Price: $65

Open Access Journals Promotions 2
Abstract

Ankylosing spondylitis (AS) is a complex autoimmune and auto-inflammatory disorder characterized by a gradual onset that can progress to spinal ankylosis over time. This chronic condition primarily affects the sacroiliac joints and the spine, often extending its influence to peripheral joints and extra-articular organs, including the eyes AS is associated with significant disability, along with comorbidities such as uveitis and inflammatory bowel disease. Moreover, individuals with AS face an elevated risk of mortality due to cardiovascular disease (CVD). This paper explores the potential benefits of statins, known for their anti-inflammatory and immunomodulatory effects, in mitigating AS-related cardiovascular risk and their therapeutic effects on disease activity.

Keywords: Ankylosing spondylitis, inflammatory disease, mortality, cardiovascular disease, immunomodulatory effects, statins.

Next »
Graphical Abstract

[1]
Brown MA, Kenna T, Wordsworth BP. Genetics of ankylosing spondylitis—insights into pathogenesis. Nat Rev Rheumatol 2016; 12(2): 81-91.
[http://dx.doi.org/10.1038/nrrheum.2015.133] [PMID: 26439405]
[2]
Mauro D, Thomas R, Guggino G, Lories R, Brown MA, Ciccia F. Ankylosing spondylitis: An autoimmune or autoinflammatory disease? Nat Rev Rheumatol 2021; 17(7): 387-404.
[http://dx.doi.org/10.1038/s41584-021-00625-y] [PMID: 34113018]
[3]
Blizzard DJ, Penrose CT, Sheets CZ, Seyler TM, Bolognesi MP, Brown CR. Ankylosing spondylitis increases perioperative and postoperative complications after total hip arthroplasty. J Arthroplasty 2017; 32(8): 2474-9.
[http://dx.doi.org/10.1016/j.arth.2017.03.041] [PMID: 28438449]
[4]
Hwang MC, Ridley L, Reveille JD. Ankylosing spondylitis risk factors: A systematic literature review. Clin Rheumatol 2021; 40(8): 3079-93.
[http://dx.doi.org/10.1007/s10067-021-05679-7] [PMID: 33754220]
[5]
Voruganti A, Bowness P. New developments in our understanding of ankylosing spondylitis pathogenesis. Immunology 2020; 161(2): 94-102.
[http://dx.doi.org/10.1111/imm.13242] [PMID: 32696457]
[6]
Tavasolian F, Lively S, Pastrello C, et al. Proteomic and genomic profiling of plasma exosomes from patients with ankylosing spondylitis. Ann Rheum Dis 2023; 82(11): 1429-43.
[http://dx.doi.org/10.1136/ard-2022-223791] [PMID: 37532285]
[7]
Tavasolian F, Inman RD. Biology and therapeutic potential of mesenchymal stem cell extracellular vesicles in axial spondyloarthritis. Commun Biol 2023; 6(1): 413.
[http://dx.doi.org/10.1038/s42003-023-04743-z] [PMID: 37059822]
[8]
Tavasolian F, Pastrello C, Ahmed Z, Jurisica I, Inman RD. Vesicular traffic-mediated cell-to-cell signaling at the immune synapse in Ankylosing Spondylitis. Front Immunol 2023; 13: 1102405.
[http://dx.doi.org/10.3389/fimmu.2022.1102405] [PMID: 36741392]
[9]
Smith JA. Update on ankylosing spondylitis: Current concepts in pathogenesis. Curr Allergy Asthma Rep 2015; 15(1): 489.
[http://dx.doi.org/10.1007/s11882-014-0489-6] [PMID: 25447326]
[10]
Zhang L, Zhang Y, Pan J. Immunopathogenic mechanisms of rheumatoid arthritis and the use of anti-inflammatory drugs. Intractable Rare Dis Res 2021; 10(3): 154-64.
[http://dx.doi.org/10.5582/irdr.2021.01022] [PMID: 34466337]
[11]
Braun J, Brandt J, Listing J, Rudwaleit M, Sieper J. Biologic therapies in the spondyloarthritis: New opportunities, new challenges. Curr Opin Rheumatol 2003; 15(4): 394-407.
[http://dx.doi.org/10.1097/00002281-200307000-00005] [PMID: 12819466]
[12]
Rosenbaum JT. Uveitis in spondyloarthritis including psoriatic arthritis, ankylosing spondylitis, and inflammatory bowel disease. Clin Rheumatol 2015; 34(6): 999-1002.
[http://dx.doi.org/10.1007/s10067-015-2960-8] [PMID: 25953065]
[13]
Cantini F, Niccoli L, Nannini C, et al. Case-control study on dactylitis, enthesitis, and anterior uveitis in spondyloarthritis associated with inflammatory bowel diseases: Role of coexistent psoriasis. J Rheumatol 2017; 44(9): 1341-6.
[http://dx.doi.org/10.3899/jrheum.161518] [PMID: 28412702]
[14]
Man S, Ji X, Hu L, et al. Characteristics associated with the occurrence and development of acute anterior uveitis, inflammatory bowel disease, and psoriasis in patients with ankylosing spondylitis: Data from the Chinese ankylosing spondylitis prospective imaging cohort. Rheumatol Ther 2021; 8(1): 555-71.
[http://dx.doi.org/10.1007/s40744-021-00293-0] [PMID: 33709320]
[15]
Tsui FWL, Lin A, Sari I, Zhang Z, Tsui HW, Inman RD. Serial Lipocalin 2 and Oncostatin M levels reflect inflammation status and treatment response in axial spondyloarthritis. Arthritis Res Ther 2021; 23(1): 141.
[http://dx.doi.org/10.1186/s13075-021-02521-y] [PMID: 33990221]
[16]
Bremander A, Petersson IF, Bergman S, Englund M. Population-based estimates of common comorbidities and cardiovascular disease in ankylosing spondylitis. Arthritis Care Res 2011; 63(4): 550-6.
[http://dx.doi.org/10.1002/acr.20408] [PMID: 21452267]
[17]
Eriksson JK, Jacobsson L, Bengtsson K, Askling J. Is ankylosing spondylitis a risk factor for cardiovascular disease, and how do these risks compare with those in rheumatoid arthritis? Ann Rheum Dis 2017; 76(2): 364-70.
[http://dx.doi.org/10.1136/annrheumdis-2016-209315] [PMID: 27283333]
[18]
Han C, Robinson DW Jr, Hackett MV, Paramore LC, Fraeman KH, Bala MV. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 2006; 33(11): 2167-72.
[PMID: 16981296]
[19]
Szabo SM, Levy AR, Rao SR, et al. Increased risk of cardiovascular and cerebrovascular diseases in individuals with ankylosing spondylitis: A population‐based study. Arthritis Rheum 2011; 63(11): 3294-304.
[http://dx.doi.org/10.1002/art.30581] [PMID: 21834064]
[20]
Papagoras C, Voulgari PV, Drosos AA. Atherosclerosis and cardiovascular disease in the spondyloarthritides, particularly ankylosing spondylitis and psoriatic arthritis. Clin Exp Rheumatol 2013; 31(4): 612-20.
[PMID: 23406817]
[21]
Mathieu S, Soubrier M. Cardiovascular events in ankylosing spondylitis: A 2018 meta-analysis. Annals of the Rheumatic Diseases 2018; 2018: 213317.
[22]
Mathieu S, Pereira B, Soubrier M, Eds. Cardiovascular events in ankylosing spondylitis: an updated meta-analysis Seminars in arthritis and rheumatism. Elsevier 2015.
[23]
Wright KA, Crowson CS, Michet CJ, Matteson EL. Time trends in incidence, clinical features, and cardiovascular disease in ankylosing spondylitis over three decades: a population-based study. Arthritis Care Res 2015; 67(6): 836-41.
[http://dx.doi.org/10.1002/acr.22512] [PMID: 25384671]
[24]
Peters MJ, van der Horst-Bruinsma IE, Dijkmans BA, Nurmohamed MT, Eds. Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis Seminars in arthritis and rheumatism. Elsevier 2004.
[25]
van der Valk FM, Bernelot Moens SJ, Verweij SL, et al. Increased arterial wall inflammation in patients with ankylosing spondylitis is reduced by statin therapy. Ann Rheum Dis 2016; 75(10): 1848-51.
[http://dx.doi.org/10.1136/annrheumdis-2016-209176] [PMID: 27084958]
[26]
Shen R, Qi L, Bai Y, Niu L, Yin X, Yu Q, et al. AB0988 genetic evidence for a bidirectional causal relationship between ankylosing spondylitis and cardiovascular disease. BMJ 2023.
[http://dx.doi.org/10.1136/annrheumdis-2023-eular.3525]
[27]
Kim J, Yoon J, Lee H, Park S, Kim S, Choe J. POS0251 Risk of cardiovascular disease associated with long-term use of non-steroidal anti-inflammatory drugs in ankylosing spondylitis. Annals of the Rheumatic Diseases 2023.
[http://dx.doi.org/10.1136/annrheumdis-2023-eular.4205]
[28]
Masi AT, Fessler SL, Brezka ML, Wang Y, Donohue SE. Systematic review and meta-analysis of individual serum lipids and analysis of lipid ratios in ankylosing spondylitis and healthy control cohorts: significantly lower mean HDL-cholesterol level in ankylosing spondylitis cohorts. Clin Exp Rheumatol 2023; 41(9): 1862-74.
[PMID: 36826790]
[29]
van der Heijde D, Sieper J, Maksymowych WP, et al. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis 2011; 70(6): 905-8.
[http://dx.doi.org/10.1136/ard.2011.151563] [PMID: 21540200]
[30]
Czókolyová M, Pusztai A, Végh E, et al. Changes of metabolic biomarker levels upon one-year anti-TNF-α therapy in rheumatoid arthritis and ankylosing spondylitis: Associations with vascular pathophysiology. Biomolecules 2021; 11(10): 1535.
[http://dx.doi.org/10.3390/biom11101535] [PMID: 34680168]
[31]
Libby P, Ridker PM, Hansson GK, Leduc Q. Inflammation in Atherosclerosis. J Am Coll Cardiol 2009; 54(23): 2129-38.
[http://dx.doi.org/10.1016/j.jacc.2009.09.009] [PMID: 19942084]
[32]
Di Meglio P, Di Cesare A, Laggner U, et al. The IL23R R381Q gene variant protects against immune-mediated diseases by impairing IL-23-induced Th17 effector response in humans. PLoS One 2011; 6(2): e17160.
[http://dx.doi.org/10.1371/journal.pone.0017160] [PMID: 21364948]
[33]
de Armas-Rillo L, Quevedo-Abeledo JC, de Vera-González A, et al. Proprotein convertase subtilisin/kexin type 9 in the dyslipidaemia of patients with axial spondyloarthritis is related to disease activity. Rheumatology 2021; 60(5): 2296-306.
[http://dx.doi.org/10.1093/rheumatology/keaa590] [PMID: 33295631]
[34]
Hussein DA, Farouk HM, Mobasher SA, El-Azizi NO, Thabet RN, Elia RZ. Atherosclerosis in Egyptian patients with ankylosing spondylitis. Egypt Rheumatol Rehabil 2014; 41(1): 1-7.
[http://dx.doi.org/10.4103/1110-161X.128127]
[35]
Kerekes G, Soltész P, Nurmohamed MT, et al. Validated methods for assessment of subclinical atherosclerosis in rheumatology. Nat Rev Rheumatol 2012; 8(4): 224-34.
[http://dx.doi.org/10.1038/nrrheum.2012.16] [PMID: 22349611]
[36]
Akar S, Can G, Binicier O, et al. Quality of life in patients with Takayasu’s arteritis is impaired and comparable with rheumatoid arthritis and ankylosing spondylitis patients. Clin Rheumatol 2008; 27(7): 859-65.
[http://dx.doi.org/10.1007/s10067-007-0813-9] [PMID: 18097710]
[37]
Mauro D, Nerviani A. Endothelial dysfunction in systemic lupus erythematosus: Pathogenesis, assessment and therapeutic opportunities. Rev Recent Clin Trials 2018; 13(3): 192-8.
[http://dx.doi.org/10.2174/1574887113666180314091831] [PMID: 29542419]
[38]
Takagi H, Mori Y, Umeda Y, et al. Abdominal aortic aneurysm with arteritis in ankylosing spondylitis. J Vasc Surg 2003; 38(3): 613-6.
[http://dx.doi.org/10.1016/S0741-5214(03)00231-3] [PMID: 12947287]
[39]
Gan F, Fei Y, Li M, et al. The characteristics of patients having ankylosing spondylitis associated with Takayasu’s arteritis. Clin Rheumatol 2014; 33(3): 355-8.
[http://dx.doi.org/10.1007/s10067-013-2444-7] [PMID: 24310108]
[40]
Dehnavi S, Sohrabi N, Sadeghi M, et al. Statins and autoimmunity: State-of-the-art. Pharmacol Ther 2020; 214: 107614.
[http://dx.doi.org/10.1016/j.pharmthera.2020.107614] [PMID: 32592715]
[41]
Toth PP, Banach M. Statins: Then and now. Methodist DeBakey Cardiovasc J 2019; 15(1): 23-31.
[http://dx.doi.org/10.14797/mdcj-15-1-23] [PMID: 31049146]
[42]
Koushki K, Shahbaz SK, Mashayekhi K, et al. Anti-inflammatory action of statins in cardiovascular disease: The role of inflammasome and toll-like receptor pathways. Clin Rev Allergy Immunol 2021; 60(2): 175-99.
[http://dx.doi.org/10.1007/s12016-020-08791-9] [PMID: 32378144]
[43]
Yebyo HG, Aschmann HE, Kaufmann M, Puhan MA. Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants. Am Heart J 2019; 210: 18-28.
[http://dx.doi.org/10.1016/j.ahj.2018.12.007] [PMID: 30716508]
[44]
Bland AR, Payne FM, Ashton JC, Jamialahmadi T, Sahebkar A. The cardioprotective actions of statins in targeting mitochondrial dysfunction associated with myocardial ischaemia-reperfusion injury. Pharmacol Res 2022; 175: 105986.
[http://dx.doi.org/10.1016/j.phrs.2021.105986] [PMID: 34800627]
[45]
Sahebkar, A., Chew, G. T., & Watts, G. F. (2014). Recent advances in pharmacotherapy for hypertriglyceridemia. Progress in lipid research, 56, 47-66.
[http://dx.doi.org/10.1016/j.plipres.2014.07.002]
[46]
Ferretti G, Bacchetti T, Sahebkar A. Effect of statin therapy on paraoxonase-1 status: A systematic review and meta-analysis of 25 clinical trials. Prog Lipid Res 2015; 60: 50-73.
[http://dx.doi.org/10.1016/j.plipres.2015.08.003] [PMID: 26416579]
[47]
Gorabi AM, Kiaie N, Pirro M, Bianconi V, Jamialahmadi T, Sahebkar A. Effects of statins on the biological features of mesenchymal stem cells and therapeutic implications. Heart Fail Rev 2021; 26(5): 1259-72.
[http://dx.doi.org/10.1007/s10741-020-09929-9] [PMID: 32008148]
[48]
Parizadeh, S. M., Azarpazhooh, M. R., Moohebati, M., Nematy, M., Ghayour-Mobarhan, M., Tavallaie, S., Rahsepar, A. A., Amini, M., Sahebkar, A., Mohammadi, M., & Ferns, G. A. (2011). Simvastatin therapy reduces prooxidant-antioxidant balance: results of a placebo-controlled cross-over trial. Lipids 46(4): 333-40.
[http://dx.doi.org/10.1007/s11745-010-3517-x]
[49]
Serban C, Sahebkar A, Ursoniu S, et al. A systematic review and meta-analysis of the effect of statins on plasma asymmetric dimethylarginine concentrations. Sci Rep 2015; 5(1): 9902.
[http://dx.doi.org/10.1038/srep09902] [PMID: 25970700]
[50]
Sohrevardi S, Nasab F, Mirjalili M, et al. Effect of atorvastatin on delirium status of patients in the intensive care unit: A randomized controlled trial. Arch Med Sci 2019; 17(5): 1423-8.
[http://dx.doi.org/10.5114/aoms.2019.89330] [PMID: 34522273]
[51]
Vahedian-Azimi A, Mohammadi SM, Banach M, Beni FH, Guest PC, Al-Rasadi K, et al. Improved COVID-19 outcomes following statin therapy: An updated systematic review and meta-analysis. Biomed Research International 2021; 2021
[52]
Sahebkar, A., Serban, C., Mikhailidis, D. P., Undas, A., Lip, G. Y., Muntner, P., Bittner, V., Ray, K. K., Watts, G. F., Hovingh, G. K., Rysz, J., Kastelein, J. J., Banach, M., & Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group (2015). Association between statin use and plasma D-dimer levels. A systematic review and meta-analysis of randomised controlled trials. Thrombosis and haemostasis 114(3): 546-57.
[http://dx.doi.org/10.1160/TH14-11-0937]
[53]
Khan MA, van der Linden SM. Ankylosing spondylitis and other spondyloarthropathies. Rheum Dis Clin North Am 1990; 16(3): 551-79.
[http://dx.doi.org/10.1016/S0889-857X(21)00888-7] [PMID: 2217958]
[54]
Myasoedova E, Karmacharya P, Duarte-Garcia A, Davis JM III, Murad MH, Crowson CS, Eds. Effect of statin use on the risk of rheumatoid arthritis: a systematic review and meta-analysis Seminars in arthritis and rheumatism. Elsevier 2020.
[55]
Bahrami A, Parsamanesh N, Atkin SL, Banach M, Sahebkar A. Effect of statins on toll-like receptors: A new insight to pleiotropic effects. Pharmacol Res 2018; 135: 230-8.
[http://dx.doi.org/10.1016/j.phrs.2018.08.014] [PMID: 30120976]
[56]
Kandelouei T, Abbasifard M, Imani D, Aslani S, Razi B, Fasihi M, et al. Effect of statins on serum level of hs-CRP and CRP in patients with cardiovascular diseases: A systematic review and meta-analysis of randomized controlled trials. Mediators Inflamm 2022; 2022: 8732360.
[http://dx.doi.org/10.1155/2022/8732360]
[57]
Sheridan A, Wheeler-Jones CPD, Gage MC. The immunomodulatory effects of statins on macrophages. Immuno 2022; 2(2): 317-43.
[http://dx.doi.org/10.3390/immuno2020021]
[58]
Satny M, Hubacek JA, Vrablik M. Statins and inflammation. Curr Atheroscler Rep 2021; 23(12): 80.
[http://dx.doi.org/10.1007/s11883-021-00977-6] [PMID: 34851454]
[59]
Coward WR, Marei A, Yang A, Vasa-Nicotera MM, Chow SC. Statin-induced proinflammatory response in mitogen-activated peripheral blood mononuclear cells through the activation of caspase-1 and IL-18 secretion in monocytes. J Immunol 2006; 176(9): 5284-92.
[http://dx.doi.org/10.4049/jimmunol.176.9.5284] [PMID: 16621994]
[60]
Blanco-Colio LM, Tuñón J, Martín-Ventura JL, Egido J. Anti-inflammatory and immunomodulatory effects of statins. Kidney Int 2003; 63(1): 12-23.
[http://dx.doi.org/10.1046/j.1523-1755.2003.00744.x] [PMID: 12472764]
[61]
Kim K-J, Kang NE, Oh YS, Jang S-E. Eupatilin alleviates hyperlipidemia in mice by inhibiting HMG-CoA reductase. Biochemistry Research International 2023; 2023
[62]
Nežić L, Amidžić L, Škrbić R, et al. Amelioration of endotoxin-induced acute lung injury and alveolar epithelial cells apoptosis by simvastatin is associated with up-regulation of Survivin/NF-kB/p65 pathway. Int J Mol Sci 2022; 23(5): 2596.
[http://dx.doi.org/10.3390/ijms23052596] [PMID: 35269738]
[63]
Klingberg E, Nurkkala M, Carlsten H, Forsblad-d’Elia H. Biomarkers of bone metabolism in ankylosing spondylitis in relation to osteoproliferation and osteoporosis. J Rheumatol 2014; 41(7): 1349-56.
[http://dx.doi.org/10.3899/jrheum.131199] [PMID: 24931960]
[64]
Balasubramanian R, Maideen NMP. HMG-CoA reductase inhibitors (Statins) and their drug interactions involving CYP enzymes, P-glycoprotein and OATP transporters-an overview. Curr Drug Metab 2021; 22(5): 328-41.
[http://dx.doi.org/10.2174/18755453MTEz9MzEj5] [PMID: 33459228]
[65]
Markowska A, Antoszczak M, Markowska J, Huczyński A. Statins: HMG-CoA reductase inhibitors as potential anticancer agents against malignant neoplasms in women. Pharmaceuticals 2020; 13(12): 422.
[http://dx.doi.org/10.3390/ph13120422] [PMID: 33255609]
[66]
Glueck CJ, Pandit R, Kumar A, Wang P, Khayznikov M, Hemachrandra K. Statin intolerance because of myalgia, myositis, myopathy, or myonecrosis can in most cases be safely resolved by vitamin d supplementation. N Am J Med Sci 2015; 7(3): 86-93.
[http://dx.doi.org/10.4103/1947-2714.153919] [PMID: 25838999]
[67]
Newman CB, Preiss D, Tobert JA, et al. Statin safety and associated adverse events: A scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol 2019; 39(2): e38-81.
[http://dx.doi.org/10.1161/ATV.0000000000000073] [PMID: 30580575]
[68]
Armitage J, Baigent C, Barnes E, Betteridge DJ, Blackwell L, Blazing M, et al. Efficacy and safety of statin therapy in older people: A meta-analysis of individual participant data from 28 randomised controlled trials. Lancet 2019; 393(10170): 407-15.
[http://dx.doi.org/10.1016/S0140-6736(18)31942-1] [PMID: 30712900]
[69]
Xie W, Huang H, Xiao S, Yang X, Zhang Z. Effect of statin use on cardiovascular events and all-cause mortality in immune-mediated inflammatory diseases: A systematic review and meta-analysis involving 148,722 participants. Pharmacol Res 2020; 160: 105057.
[http://dx.doi.org/10.1016/j.phrs.2020.105057] [PMID: 32619724]
[70]
van Denderen JC, Peters MJ, van Halm VP, van der Horst-Bruinsma IE, Dijkmans BA, Nurmohamed MT. Statin therapy might be beneficial for patients with ankylosing spondylitis. Ann Rheum Dis 2006; 65(5): 695-6.
[http://dx.doi.org/10.1136/ard.2005.044503] [PMID: 16219702]
[71]
Braun J, Landewé R, Hermann KGA, et al. Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: Results of a multicenter, randomized, double‐blind, placebo‐controlled magnetic resonance imaging study. Arthritis Rheum 2006; 54(5): 1646-52.
[http://dx.doi.org/10.1002/art.21790] [PMID: 16646033]
[72]
Van Denderen JC, Peters M, van Halm V, van der Horst-Bruinsma I, Dijkmans B, Nurmohamed M. Statin therapy might be beneficial for treating patients with ankylosing spondylitis. Ann Rheum Dis 2005.
[73]
Burtică SN, Bruckner IV, Gurghean A. Statin therapy in patients with ankylosing spondylitis. Age 35: 10.
[74]
Heslinga SC, Peters MJ, ter Wee MM, et al. Reduction of inflammation drives lipid changes in ankylosing spondylitis. J Rheumatol 2015; 42(10): 1842-5.
[http://dx.doi.org/10.3899/jrheum.150193] [PMID: 26329334]
[75]
Oza A, Lu N, Schoenfeld SR, et al. Survival benefit of statin use in ankylosing spondylitis: A general population-based cohort study. Ann Rheum Dis 2017; 76(10): 1737-42.
[http://dx.doi.org/10.1136/annrheumdis-2017-211253] [PMID: 28698231]
[76]
Semb AG, Rollefstad S. CVD prevention and statin therapy in ankylosing spondylitis. Nat Rev Rheumatol 2016; 12(8): 441-2.
[http://dx.doi.org/10.1038/nrrheum.2016.103] [PMID: 27357255]
[77]
Semb AG, Kvien TK, DeMicco DA, et al. Effect of intensive lipid‐lowering therapy on cardiovascular outcome in patients with and those without inflammatory joint disease. Arthritis Rheum 2012; 64(9): 2836-46.
[http://dx.doi.org/10.1002/art.34524] [PMID: 22576673]
[78]
Dau J, Ed. Associations of statin usage with disease activity in ankylosing spondylitis. 2018 ACR/ARHP Annual Meeting.
[79]
Moon J, Lee SY, Na HS, et al. Ezetimibe ameliorates clinical symptoms in a mouse model of ankylosing spondylitis associated with suppression of Th17 differentiation. Front Immunol 2022; 13: 922531.
[http://dx.doi.org/10.3389/fimmu.2022.922531] [PMID: 36059546]
[80]
van de Peppel IP, Bertolini A, van Dijk TH, Groen AK, Jonker JW, Verkade HJ. Efficient reabsorption of transintestinally excreted cholesterol is a strong determinant for cholesterol disposal in mice. J Lipid Res 2019; 60(9): 1562-72.
[http://dx.doi.org/10.1194/jlr.M094607] [PMID: 31324653]
[81]
Yan Y, He F, Li Z, et al. The important role of apolipoprotein A-II in ezetimibe driven reduction of high cholesterol diet-induced atherosclerosis. Atherosclerosis 2019; 280: 99-108.
[http://dx.doi.org/10.1016/j.atherosclerosis.2018.11.016] [PMID: 30500605]
[82]
Dau J, Weisman M, Lee M, Ward M, Brown M, Diekman L, et al. SAT0400 Clinical Factors Impacting Statin Usage in A Longitudinal Ankylosing Spondylitis Cohort. BMJ Publishing Group Ltd 2016.
[http://dx.doi.org/10.1136/annrheumdis-2016-eular.3225]
[83]
Slobodnick A, Shah B, Krasnokutsky S, Pillinger MH. Update on colchicine, 2017. Rheumatology 2018; 57 (Suppl. 1): i4-i11.
[http://dx.doi.org/10.1093/rheumatology/kex453] [PMID: 29272515]
[84]
Wibetoe G, Ikdahl E, Kvien TK, Rollefstad S, Semb AG. SAT0395 statin treatment in patients with ankylosing spondylitis. BMJ Publishing Group Ltd 2016.
[http://dx.doi.org/10.1136/annrheumdis-2016-eular.5534]
[85]
Garg N, Krishan P, Syngle A. Rosuvastatin improves endothelial dysfunction in ankylosing spondylitis. Clin Rheumatol 2015; 34(6): 1065-71.
[http://dx.doi.org/10.1007/s10067-015-2912-3] [PMID: 25771851]

Rights & Permissions Print Cite
Article Metrics
11
Wayfinder Image
Open Access Journals Promotions
© 2024 Bentham Science Publishers | Privacy Policy